【DPHARMA 7148 交流专区】（前名 CCMDBIO）

icy97

馬化工聯藥 末季淨利漲38%
  
2016年2月23日
（吉隆坡23日訊）馬化工聯藥（CCMDBIO，7148，主要板消費）去年收購6家製藥設備公司后，2015財年營業額漲53%，從1億7696萬令吉攀升至2億7068萬令吉，競標業務取得的政府醫院需求增長亦提振業績，全年淨利攀升10%至3878萬令吉。

該公司建議末季每股派息5.5仙，使全年股息增至9.5仙。

該公司截至12月底末季，淨利按年起38%至1534萬令吉，受惠于需求成長及其他收入增加；營業額漲75%，達8940萬令吉。

馬化工聯藥總執行長倫納德阿立夫發布文告指出，雖然令吉貶值將影響公司生產和營運成本，製藥領域需求料持穩。他估計匯率波動和經濟不穩定，或對製造賺幅帶來壓力。

在現有挑戰環境下，馬化工聯藥謹慎樂觀看待2016財年將交出讓人滿意表現。【中国报财经】

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2015	31 Dec 2014	31 Dec 2015	31 Dec 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	89,401	51,024	270,680	176,961
2	Profit/(loss) before tax	17,529	13,921	49,755	46,509
3	Profit/(loss) for the period	17,529	13,921	49,755	46,509
4	Profit/(loss) attributable to ordinary equity holders of the parent	15,335	11,119	38,775	35,271
5	Basic earnings/(loss) per share (Subunit)	9.19	8.01	19.17	25.41
6	Proposed/Declared dividend per share (Subunit)	5.50	14.50	9.50	18.50
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6200		1.3900

icy97

EX-date	06 Jun 2016
Entitlement date	08 Jun 2016
Entitlement time	05:00 PM
Entitlement subject	Final Dividend
Entitlement description	Final Tax Exempt Dividend of 5.5 sen per ordinary share
Period of interest payment	to
Financial Year End	31 Dec 2015
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	TRICOR INVESTOR & ISSUING HOUSE SERVICES SDN BHDUnit 32-01, Level 32, Tower A,Vertical Business Suite, Avenue 3, Bangsar South,No. 8, Jalan Kerinchi59200Kuala LumpurTel:0327839299Fax:0327839222
Payment date	28 Jun 2016
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	08 Jun 2016
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.0550
Par Value	Malaysian Ringgit (MYR) 0.500

icy97

馬化工聯藥 1.4億建新廠房倉庫

2016年3月22日
（吉隆坡22日訊）馬化工聯藥（CCMDBIO，7148，主要板消費）以總額1億4080萬令吉，建築一個新的廠房和倉庫。

該公司向馬證交所報備，將分別以1億370萬令吉和3710萬令吉，建築一個新的廠房和倉庫。

其中新廠房將涵蓋兩個相鄰大樓，備有設施可迎合現有業務，並提升產品類別。一旦竣工后，將提高公司產能約40%至50%。

至于設有泊車設施的倉庫，將配合現有營運及未來倉庫需求。

上述建築工程將在今年第3季動工，估計可在2018年末季完工。至于建築資金，其中1億1330萬令吉是在去年通過附加股集資取得，余額將通過內部融資或銀行貸款取得。【中国报财经】

Type	Announcement
Subject	OTHERS
Description	CONSTRUCTION OF NEW PLANT (INCLUDING MACHINERIES) AND NEW WAREHOUSE WITH ROOF TOP CAR PARK
The Board of Directors of CCM Duopharma Biotech Berhad (“CCMD” or “the Company”) wishes to announce that the Company will be constructing a new state of the art plant (including machineries) and a new warehouse with roof top car park at Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya and Lot 2707, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, at an estimated cost of RM103.7 million and RM37.1 million (excluding GST), respectively. For full details of the announcement, please refer to the attached file. This announcement is dated 22 March 2016.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5037401

Attachments Announcement on Construction of New Plant and Warehouse with Roof Top Car Park 22.3.16.pdf

Type	Announcement
Subject	OTHERS
Description	CONSTRUCTION OF NEW PLANT (INCLUDING MACHINERIES) AND NEW WAREHOUSE WITH ROOF TOP CAR PARK
We refer to the announcement dated 22 March 2016 in relation to the construction of the new plant (including machineries) and new warehouse with roof top car park. This is the amended announcement to rectify the typographical error in Item 8, which should read as follows: "8.       INTERESTS OF DIRECTORS, MAJOR SHAREHOLDERS AND PERSONS CONNECTED None of the Directors and/or substantial shareholders of CCMD and persons connected to them have any interest, direct or indirect, in the said construction of the new plant (including machineries) and new warehouse with roof top car park."

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5037913

Attachments Announcement on Construction of New Plant and Warehouse with Roof Top Car Park 22.3.16 (3).pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2016	31 Mar 2015	31 Mar 2016	31 Mar 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	79,470	45,599	79,470	45,599
2	Profit/(loss) before tax	9,941	12,198	9,941	12,198
3	Profit/(loss) for the period	7,828	8,969	7,828	8,969
4	Profit/(loss) attributable to ordinary equity holders of the parent	7,843	8,969	7,843	8,969
5	Basic earnings/(loss) per share (Subunit)	2.81	6.43	2.81	6.43
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6400		1.6100

icy97

Date of change	26 May 2016
Name	TAN SRI DATO' DR ABU BAKAR SULEIMAN
Age	72
Gender	Male
Nationality	Malaysia
Designation	Chairman
Directorate	Non Independent and Non Executive
Type of change	Retirement
Qualifications	1. Bachelor of Medicine and Bachelor of Surgery, Monash University, Australia2. Master of Medicine, University of Singapore3. Fellow, Royal Australian College of Physicians4. Fellow, Royal College of Physicians, London5. Fellow, Royal College of Physicians, Edinburgh6. Fellow, Royal College of Physicians, Glasgow7. Fellow, Royal College of Physicians, Ireland8. Fellow, Academy of Medicine, Malaysia9. Fellow, Academy of Medicine, Singapore10. Fellow, Academy of Science, Malaysia11. Honorary Fellow, American College of Physicians
Working experience and occupation	Tan Sri Dato Dr. Abu Bakar began  his career as a Medical Officer with the Ministry of Health (MOH) in 1969. He subsequently completed his training in Internal Medicine and became a Consultant Physician with the Department of Nephrology, Kuala Lumpur Hospital. He has held various top level positions in the medical field, including being Head of Department  of Nephrology, Kuala Lumpur Hospital, where he worked for 11 years. In 1987, he was appointed MOHs Director of Medical Services and in 1989, the Deputy Director-General of Health. He went on to become the Director-General of Health, a position he held from 1991 to 2001. He attended the Advanced Management Program at Harvard Business School, USA, in 1991. Upon his official retirement in 2001, he was appointed President of the International Medical University, a position he currently holds. He is also the Chairman of IHH Healthcare Berhad.
Family relationship with any director and/or major shareholder of the listed issuer	None
Any conflict of interests that he/she has with the listed issuer	None
Details of any interest in the securities of the listed issuer or its subsidiaries	(i) 575,000 ordinary shares directly held (ii) 56,400 ordinary shares indirectly held

icy97

Date of change	26 May 2016
Name	PUAN NORMALA BINTI ABDUL SAMAD
Age	53
Gender	Female
Nationality	Malaysia
Designation	Chairman
Directorate	Non Independent and Non Executive
Type of change	Appointment
Qualifications	1. Masters in Business Administration Majoring in Human Resource from Nottingham Trent University, United Kingdom2. Bachelor of Administration Management from Paramount University of Technology, United Kingdom3. Diploma in Professional Safety Management from Construction and Industrial Safety Training Centre (CONSIST), Australia4. Diploma in Human Resource Administration from Malaysian Institute of Personnel Management (MIPM)5. Certificate in Personnel Management from MIPM6. Certificate in Safety & Health Officer from the National Institute of Safety & Health (NIOSH)
Working experience and occupation	YB Puan Hajah Normala is currently the Member of Parliament for Pasir Gudang Constituency in Johor since 2013. She is also a Committee member of the International Bureau of Wanita UMNO Malaysia and a member of the Wanita UMNO for Johor State. In addition, she is the Chief of the UMNO's Women's Wing for Pasir Gudang Division. Before her foray into politics, YB Hajah Puan Normala accumulated over 32 years of experience in Human Resources and Workers Safety and Health. She began her career in Human Resource in 1981 with Pan Century Edible Oils Sdn Bhd, Pasir Gudang and progressed to the position of Head of Human Resources in 1992 at Pan Century Oleochemicals Sdn Bhd. She later joined Grand Bank Yachts Sdn Bhd in 1995 as a Human Resources Manager and resigned in 2013. YB Hajah Normala is very active in non-governmental organisations and holds various position such as the Chairman of Mimbar Permuafakatan Ibu Bapa Malaysia (MAPIM), Pasir Gudang and Supreme Council Member of MAPIM (National Level), Chairman the Women's Bureau of Drug Prevention Association of Malaysia (PEMADAM) Johor, Chairman of the Development Council of Women & Family for Pasir Gudang, Chairman of Perkumpulan Wanita (PERWANI) Parliament Pasir Gudang, Chairman and Founder of Koperasi Seri Cempaka Pasir Gudang Berhad and Chairman of the Advisory Board of Community College Pasir Gudang.She was the former Deputy Chairman of Federation of Malaysia Manufacturers (FMM), Johor Branch since 2000 and also chaired various committees on FMM. She was the former Deputy Chairman of Human Resources Officers Group for Pasir Gudang Industrial Area, former Deputy Chairman of Malaysian Employees Federation Johor, Honorary Secretary of Malaysian Association of Safety and Health Officers, former Panel Member of Appeal Cases Committee for Court of Appeals SOCSO cases and former Panel Member of Industrial Court Malaysia.
Directorships in public companies and listed issuers (if any)	Chemical Company of Malaysia Berhad

icy97

生技药物2年内面市．马化学药业冀赚幅回升至40%

马化学药业（CCMDBIO，7148，主板消费品组）多管齐下克服利润走低问题，并希望生技药物约24个月内面市后，可使赚幅回复至约40%水平，谨慎乐观看待现财政年可维持满意业绩。

该集团首席执行员李奥纳阿里夫说，进口成本达90%，确实在马币波动期侵蚀利润，以10%出口作为自然护盘抵销程度有限。

料9个月后有利润

他日前在股东大会指出，除了监控制造与营运、深耕生物科技药物策略增强利润外，公司也期望新生技产品比重从目前的约1%，提高至2020年的25%和占出口30%。

他说，虽然马币前些时短暂回扬带来向好，基于这些效应期通常达6至8个月，预定9至10个月后才会提振利润。

基于马币波动促使营运环境深具挑战，该集团对2016财政年捎来满意业绩保持谨慎乐观。

“马币波动对其业务冲击而侵蚀毛利，在目前这个时候仍不能完全免疫。”

刚公布的2016年3月31日首季业绩，马化学药业受马币波动所累，促成生产成本走高压缩毛利，税前盈利按年18.5%至994万令吉，并且蒙受净亏损达25万令吉，相比前期净利395万4千令吉。

马币贬影响毛利净亏

马化学药业的去年首季毛利，约为45%至52%，惟基于马币因素，促使其毛利受创而招致净亏。

他指出，尤其最近一年，业务50%供应给政府医院，油价下跌也促使政府医院减供药品给病黎，期望油价回弹至50美元以上后政府对医疗保健开销正常化。

他说，内部管控成本措施将实施2至3年期，该公司也采取线上采购方式，以更竞争的价格获得供应商供应所需货品。

与印度韩策略结盟

他披露，马化学药业已与印度、韩国展开策略结盟已攻打生物科技药物市场，与印度的结盟而获在马、新、汶独家经销胰岛素，惟赚幅没在马制造生产那么可观。

他说，用以控制血癌病情的红血球生成素（Erythropoietin，简称EPO），则是与韩国PanGen生物科技有限公司结盟，以加快进军生技仿制药（Biosimilar）领域。其母公司马化学（CCM，2879，主板工业产品组）在韩国生技公司持股11.6%股权，母公司持有马化学药业约70%股权。

他指出，初期只是从韩国进口成品在马推出，第二阶段则会在马大批进口与最后整装及推出市场，经过临床试验与获取所需认证，预料5至10年透过工艺转移后可在马生产制造。

他说，未来也将鉴定3至4样肿瘤科药物，并与更多策略伙伴合作，以同样模式开发需求广泛而利润不错的生技药物。

该集团未来两、三年斥资1亿4千万令吉在巴生良木园扩建工厂，今年巴生厂房资本开销约5千万令吉。

今日股东大会上，主席丹斯里阿布峇卡与董事丹斯里惹卡迪申宣布退休，公司去年另委丹斯里西蒂莎莉亚和韩国籍董事入局。马化学药业将实现董事局内有30%女性之愿景。

文章来源：
星洲日报／投资致富．企业故事．文：张启华．2016.06.19

otkkalahteruk

有谁现在握着这间公司？

Tony-Pua

7148    CCMDBIO    CCM DUOPHARMA BIOTECH BHD

Interim Single Tier Dividend 2.5 sen

Entitlement Details: Interim Single Tier Dividend of 2.5 sen per ordinary share Entitlement Type: Interim Dividend Entitlement Date and Time: 21/10/2016  05:00 PM Year Ending/Period Ending/Ended Date: 31/12/2016 EX Date: 19/10/2016 To SCANS Date: Payment Date: 11/11/2016

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2016	30 Jun 2015	30 Jun 2016	30 Jun 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	79,135	56,308	158,605	101,907
2	Profit/(loss) before tax	7,723	8,407	17,664	20,605
3	Profit/(loss) for the period	3,941	5,848	11,769	14,817
4	Profit/(loss) attributable to ordinary equity holders of the parent	4,503	5,848	12,346	14,817
5	Basic earnings/(loss) per share (Subunit)	1.41	4.19	4.22	10.59
6	Proposed/Declared dividend per share (Subunit)	2.50	4.00	2.50	4.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6000		1.6100

icy97

马化学药业盈利先蹲后跳

（吉隆坡15日讯）特朗普胜选恐使跨太平洋伙伴关系协议（TPP）陷入停摆，将让马化学药业（CCMDBIO，7148，主板消费品组）等学名药（Generic Drugs）制造商受惠，但肯纳格研究指出，集团短期内仍面对重组成本和低赚益压力，2016财政年盈利恐大跌逾30%。

今年盈利恐跌逾30%．明后年可显著复苏

但是，鉴于集团已落实两大措施有望提振中长期盈利增长，预期2017和2018财政年盈利将显著复苏。

肯纳格研究表示，特朗普意外胜选，市场普遍相信在贸易保护主义抬头下，TPP洽商将束之高阁，但对马化学药业等学名药制造商将带来加分效果，主要是延长专利权期限的规范将取消。

该行补充，在政府医院需求增加，以及新业务带来6个月贡献下，马化学药业2015财政年营业额增长52.5%，但净利增长则受重组相关成本影响，仅按年增长3.2%，相信高分销成本和总赚益压力犹在，可能对盈利带来影响，预见2016财政年盈利将下跌31.1%。

两大措施推动中长期盈利

“有鉴于此，我们不给予其投资评级，目标价则为1令吉96仙。”

不过，肯纳格研究说，马化学药业已落实两大措施来推动中长期盈利表现，预期2017和2018财政年盈利将复苏32.6%和14.5%。

首先，马化学药业与区域制药公司策略结盟将逐步开花结果，其中集团将专注于生物治疗药物（Bio-therapeutics）和肿瘤学（Oncology）领域。

但肯纳格研究说，尽管相关领域快速增长，马化学药业却以低赚益进行分销，相信随着红血球生成因子（EPO）生技仿制药（Biosimilar）将在2017年杪投产，加上制造资产持续扩充，将可使得集团取得更高的赚益。

未来5年投入3亿资本开销

此外，马化学药业也拟在未来5年投入3亿令吉资本开销，为长期业务增长铺路。肯纳格研究认为，业务扩张虽是汰旧换新的必要之举，以符合美国食品药品监督管理局（FDA）准则，进而进军更多市场，但阵痛期可能很长。

“但是，这和美国与欧盟制药公司面对的专利悬崖（Patent cliff）问题，将使得马化学药业可从学名药制造中获利。”

文章来源：
星洲日报‧财经‧报道：洪建文‧2016.11.15

哭哭鸟

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2016	30 Sep 2015	30 Sep 2016	30 Sep 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	80,302	79,732	238,907	181,279
2	Profit/(loss) before tax	7,516	11,631	25,180	32,226
3	Profit/(loss) for the period	6,226	8,633	17,995	23,440
4	Profit/(loss) attributable to ordinary equity holders of the parent	6,341	8,633	18,867	23,440
5	Basic earnings/(loss) per share (Subunit)	2.23	5.18	6.45	14.04
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6200		1.6100

icy97

Type	Announcement
Subject	OTHERS
Description	USD4 MILLION REVOLVING CREDIT FACILITY (RC FACILITY) FROM SUMITOMO MITSUI BANKING CORPORATION LABUAN BRANCH (SMBC)
The Board of Directors of CCM Duopharma Biotech Berhad (“CCMD” or “the Company”) wishes to announce that the Company has entered into an agreement with Sumitomo Mitsui Banking Corporation, Labuan Branch (“SMBC”) on 7 December 2016 for a USD4 million RC Facility to be cross utilized by its wholly owned subsidiary, CCM International (Philippines), Inc. (“CCMIP”), upon the terms and conditions as contained in the Bank’s offer letter dated 18 November 2016.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5283613

Attachments Announcement on Acceptance of RC Facility 7.12.pdf

icy97

CCM Duopharma获3亿合约 为政府医院提供人胰岛素
By Sulhi Azman / theedgemarkets.com   | January 25, 2017 : 4:18 PM MYT

（吉隆坡25日讯）CCM Duopharma Biotech Bhd宣布，独资子公司CCM Pharmaceuticals私人有限公司（CCMP）已获得卫生部的3亿4万令吉合约，为所有政府医院和诊所提供人胰岛素。

CCM Duopharma今日向大马交易所报备，该合约为期3年，从2016年12月2日至2019年12月1日。

CCMP是人胰岛素的代理商。该人胰岛素由柔佛努沙再也的Biocon私人有限公司制造。

人胰岛素是合成胰岛素的名称，是在实验室中仿制人类中的胰岛素。

该公司今日在文告指出：“决标信的条款将通过CCMP、Biocon和卫生部在日后签署正式协议而确定。”

该公司补充：“然而，公司已经开始向卫生部提供该产品。”

据估计，大马有350万名糖尿病患者，其中35万人在政府医院和诊所使用人胰岛素治疗。

“CCMP和Biocon希望通过提供高素质和具成本效益的生物胰岛素，改善国内的糖尿病管理。”

CCM Duopharma由Chemical Company of Malaysia Bhd（CCM）控有73.37%股权，并通过CCMP销售医药产品。

除了大马作为主要市场，CCM Duopharma还在新加坡、越南、印尼、毛里求斯、马尔代夫及菲律宾销售产品。

同时，Biocon是印度最大制药公司Biocon Ltd的一份子。该公司于2010年进入大马，投资约2亿5000万美元建立一个综合胰岛素制造厂房。

（编译：陈慧珊）

Type	Announcement
Subject	OTHERS
Description	ACCEPTANCE OF TENDER OFFER (HEREINAFTER REFERRED TO AS LETTER OF AWARD) FOR THE SUPPLY OF HUMAN INSULIN FORMULATIONS (HEREINAFTER REFERRED TO AS PRODUCTS) UNDER MINISTRY OF HEALTHS (MOH) OFF-TAKE AGREEMENT PROGRAM
The Board of Directors of CCM Duopharma Biotech Berhad (“CCMD” or “the Company”) wishes to announce that the Government of Malaysia had accepted the tender offer (hereinafter referred to as “Letter of Award” or “LOA”) from Biocon Sdn Bhd to manufacture and supply, and for CCM Pharmaceuticals Sdn Bhd (hereinafter referred to as “CCMP”) to deliver the Products under the Ministry of Health’s Off-Take Agreement Program. CCMP is a wholly owned subsidiary of CCMD. For full details of the announcement, please refer to the attched file. The announcement is dated 25 January 2017.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5324369

Attachments CCMP - Ann Biocon Final (25012017).docx

icy97

CCM Duopharma寻求销售用于肾衰竭治疗的促红细胞生成素
By Sulhi Azman  / theedgemarkets.com   | February 15, 2017 : 8:11 PM MYT

（吉隆坡15日讯）CCM Duopharma Biotech Bhd将为促红细胞生成素（EPO）生物仿制药注册，此举将有利于治疗末期肾衰竭患者的贫血。

这是继CCM Duopharma独资子公司Duopharma（马）私人有限公司（DMSB）与韩国上市公司PanGen Biotech Inc完成为期两年的临床试验后的进展，此临床试验的投资成本共计1750万令吉。

CCM Duopharma的母公司Chemical Co of Malaysia Bhd（CCM）持有PanGen的9.34%股权。

通过在这项临床试验的投资，CCM Duopharma表示，该集团获得这个EPO生物仿制药在大马、新加坡和汶莱的产品营销及分销权。

该集团在今日的一则文告中指出：“一旦获得全国药品监管机构的营销授权后，这项产品预计将推出市面。”

CCM Duopharma指出，该集团是大马首家共同开发生物治疗产品的公司，以及全球第二家开发重组人促红细胞生成素（epoetin-alfa）生物仿制药的公司。

根据该集团，这项临床试验涉及大马的228名病患，以及韩国的70名病患，并对这些病患进行多个研究中心、多国、双盲、随机、平行、活性对照的临床试验，藉此评估PanGen的EPO产品（代号为PDA10）在慢性肾衰竭引起贫血的病患中的安全性和有效性。

“PDA10显示出与药物动力学、药效学和毒性等价的创新药物类似的功效及安全性。”

PDA10是PanGen的首个商业生物仿制药品，使用重组脱氧核糖核酸（DNA）技术在细胞培养中产生的促红细胞生成素，负责制造人类的红细胞。

CCM集团董事经理兼CCM Duopharma总执行长Leonard Ariff Abdul Shatar说：“完成第3阶段的临床试验，这对我们来说是一个重要的里程碑，因为我们扩大对生物仿制药的关注，同时也间接有助大马生物制药业的发展。它也使我们能够为患者提供可负担的治疗选择，且不会影响安全性和疗效。”

“生物仿制药或后继生物药（follow-on biologics）用来形容正式获得批准后续版本的创新生物制药产品的术语，并由不同的赞助商在创新产品的专利和独家经销权届满后制造。

“这项生物仿制药业务在亚洲预计将录得12%的复合年增长率（CAGR），2020年东南亚料增长至80亿令吉。”

（编译：倪嫣鴽）

Type	Announcement
Subject	OTHERS
Description	SUCCESSFUL COMPLETION OF JOINTLY CONDUCTED MULTINATIONAL PHASE III CLINICAL TRIAL FOR BIOSIMILAR ERYTHROPOIETIN
The Board of Directors of CCM Duopharma Biotech Berhad (“CCMD” or “the Company”) wishes to announce that its wholly owned subsidiary, Duopharma (M) Sdn Bhd (DMSB), and PanGen Biotech, Inc. (hereinafter referred to as “PanGen”), an investee company of Chemical Company of Malaysia Berhad (hereinafter referred to as “CCM”), has successfully completed a joint Phase III Clinical Trial (hereinafter referred to as the “Joint Clinical Trial”) for Biosimilar Erythropoietin or EPO (code-named as “PDA10”)  in Korea and Malaysia. For full details of the announcement, please refer to the attached file. This announcement is dated 15 February 2017.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5337557

Attachments PanGen Joint Clinical Trial (Bursa ANN wo PR).doc

icy97

CCM Duopharma末季净利跌35% 派息4仙
By Adela Megan Willy / theedgemarkets.com   | February 24, 2017 : 6:59 PM MYT

（吉隆坡24日讯）CCM Duopharma Biotech Bhd 2016财政年末季（截至2016年12月31日止）净利跌挫35.3%至993万令吉，相比同期净赚1534万令吉。

这家制药公司今日通过大马交易所发布文告指，末季营业额也从上财年同季的8940万令吉，按年下跌17.2%至7403万令吉。

总结2016财年的业绩表现，CCM Duopharma净赚2781万令吉，2015财年净利报3570万令吉，跌幅为22.1%。

该集团将全年净利下滑的原因归咎于产品组合的变化，以及生产成本因外汇波动而增加，因而导致总赚幅减少。

累计4季营业额报3亿1294万令吉，同期共计2亿6979万令吉，增幅为16%，主要得益于近期收购子公司的全年营收贡献，相较于2015财年仅7个月的营收进账。

此外，CCM Duopharma宣布，2016财年派发每股4仙的单层终期股息，派息日定于2017年6月23日。

尽管制造业势头或持续受令吉疲弱而承压，但CCM预测，制药领域仍保持稳定。

此外，持续的外汇波动和经济不确定性，或使该集团的制造业务赚幅进一步承压。

“鉴于当前的环境充满挑战，若无任何意外的话，本集团乐观看待2017财年或取得令人满意的业绩表现。”

（编译：倪嫣鴽）

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2016	31 Dec 2015	31 Dec 2016	31 Dec 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	74,033	89,401	312,940	269,794
2	Profit/(loss) before tax	6,299	17,529	31,479	47,829
3	Profit/(loss) for the period	9,522	15,335	27,517	36,391
4	Profit/(loss) attributable to ordinary equity holders of the parent	9,926	15,335	27,808	35,699
5	Basic earnings/(loss) per share (Subunit)	3.41	9.19	9.86	18.05
6	Proposed/Declared dividend per share (Subunit)	0.04	0.06	0.07	0.10
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6300		1.6100

icy97

EX-date	26 May 2017
Entitlement date	30 May 2017
Entitlement time	05:00 PM
Entitlement subject	Final Dividend
Entitlement description	Final Single Tier Dividend of 4.0 sen per ordinary share.
Period of interest payment	to
Financial Year End	31 Dec 2016
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	TRICOR INVESTOR & ISSUING HOUSE SERVICES SDN BHDUnit 32-01, Level 32, Tower A,Vertical Business Suite, Avenue 3, Bangsar South,No. 8, Jalan Kerinchi59200 Kuala LumpurTel:0327839299Fax:0327839222
Payment date	23 Jun 2017
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	30 May 2017
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.04
Par Value	Malaysian Ringgit (MYR) 0.000

icy97

马化工Biocon Natco Pharma
携手生产低价胰岛素肿瘤药

2017年4月4日
（吉隆坡3日讯）马化工（CCM，2879，主板工业产品股）子公司CCM Duopharma Biotech Berhad（CCMD），与Biocon有限公司和Natco Pharma有限公司成立策略联盟，在国内提供价格合理的癌症和胰岛素治疗。

马化工今日发表文告，CCDM与Natco的合作关系已迈入第15年，通过咨询服务、技术转让和供应协议，在国内设立高效原料药（HAPI）厂房，生产普通肿瘤药物。

通过战略合作，Natco将提供设备设计、制造技术转让，及活性医药物成分（API），以供未来7年内，制造8种抗癌症产品。

同时，该公司指出，马来西亚表现和传递单位（PEMANDU）已将上述项目提交给关键经济领域（NKEA）的启动计划（EPP），预计CCMD的投资额将达3400万令吉。

另一方面，CCMD子公司CCM Pharmaceuticals私人有限公司（CCPM），获Biocon颁发总值3亿令吉合约，为政府医院和诊所供应人体胰岛素。

合约为期3年，截止于2019年12月1日。【e南洋】

icy97

CCM Duopharma首季净利跳涨22% 药物需求走高
Adam Aziz/theedgemarkets.com
May 22, 2017 16:58 pm MYT

（吉隆坡22日讯）基于CCM Duopharma Biotech Bhd与业务合作伙伴开始分销胰岛素（insulin），该集团2017财政年首季（截至2017年3月31日止）的净利按年增长22%至956万令吉，上财年同季则净赚784万令吉

CCM Duopharma今日向大马交易所报备，政府医院的需求增加也对推高该集团的单季净利居功至伟。

首季营业额劲扬55%至1亿2331万令吉，上财年同季报7947万令吉。

瞻望未来，尽管CCM Duopharma的生产及营运成本受令吉走贬所冲击，但该集团估计，制药业在2017年将保持稳定走势。

“持续的外汇波动及经济不明朗因素将令本集团的制造赚幅进一步承压。”

即便如此，该集团仍“乐观”看待2017财年或取得令人满意的业绩表现。

（编译：倪嫣鴽）

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2017	31 Mar 2016	31 Mar 2017	31 Mar 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	123,306	79,470	123,306	79,470
2	Profit/(loss) before tax	12,122	9,941	12,122	9,941
3	Profit/(loss) for the period	9,564	7,828	9,564	7,828
4	Profit/(loss) attributable to ordinary equity holders of the parent	9,564	7,843	9,564	7,843
5	Basic earnings/(loss) per share (Subunit)	3.43	2.81	3.43	2.81
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	1.6600		1.6300

icy97

融资新厂买机械
马化工药业获2.8亿贷款

2017年6月20日
（吉隆坡20日讯）马化工药业（CCMDBIO，7148，主板消费产品股）宣布从大马银行（AMBANK，1015，主板金融股）旗下大马回教银行（AmBank Islamic），取得共2亿8000万令吉的融资便利。

马化工药业今日向交易所报备，分别从大马回教银行取得2亿5000万令吉的Murabahah Tawarruq 短期融资便利（Term Financing Facility，简称TF-i），以及3000万令吉的回教多边贸易便利（Islamic Multi-trade facilities，简称MTF-i）。

为期10年的Murabahah Tawarruq 短期融资便利，将用来融资新厂房的资本开销、扩展或建筑，以及购买机械。

同时也会利用回教多边贸易便利，作为新厂房的资本开销、扩展或建筑、购买机械及业务营运。

预计上述融资便利将提高公司的负债，从0.25倍增加至0.87倍。【e南洋】

Type	Announcement
Subject	OTHERS
Description	ACCEPTANCE OF MURABAHAH TAWARRUQ TERM FINANCING FACILITY OF RM250 MILLION (TF-i) AND ISLAMIC MULTI TRADE FACILITIES OF RM30 MILLION (MTF-i) FROM AMBANK ISLAMIC BERHAD (AMBANK OR BANK)
The Board of Directors of CCM Duopharma Biotech Berhad (“CCMD” or “the Company”) wishes to announce that the Company has entered and executed the following facilities with Ambank Islamic Berhad (“Ambank”): 1. Murabahah Tawarruq Term Financing Facility of RM250 million ("TF-i") 2. Islamic Multi-Trade Facilities of RM30 million ("MTF-i") (Collectively referred to as the "Facilities") Please refer attachment below.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5465189

Attachments Bursa Announcement - TFi and MTFi frm AmBank of RM250mil and RM30mil respectively (Final).doc